Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 12:23:45 2024-04-18 pm EDT 5-day change 1st Jan Change
20.36 USD +1.34% Intraday chart for Fulgent Genetics, Inc. -3.30% -29.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating MT
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024 CI
Transcript : Fulgent Genetics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 Revenue $70.5M MT
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 EPS $0.28 MT
Cooper Unit, Fulgent Genetic to Offer Newborn Genetic Screening Panels MT
Cord Blood Registry by CooperSurgical, Inc. and Fulgent Genetics, Inc. Launch Innovative Genetic Testing CI
UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target MT
Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting CI
Transcript : Fulgent Genetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. CI
Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2023 CI
Insider Sell: Fulgent Genetics MT
Sector Update: Health Care Stocks Steady Premarket Friday MT
Transcript : Fulgent Genetics, Inc., Q2 2023 Earnings Call, Aug 04, 2023
Fulgent Genetics Swings to Loss in Q2, Revenue Declines; Raises Guidance; Shares Surge 10% Pre-Bell MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. CI
Fulgent Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023 CI
North American Morning Briefing : Stocks Seen -2- DJ
Fulgent Genetics, Inc.(NasdaqGM:FLGT) added to Russell 2000 Value-Defensive Index CI
Chart Fulgent Genetics, Inc.
More charts
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
20.09 USD
Average target price
26.67 USD
Spread / Average Target
+32.74%
Consensus
  1. Stock Market
  2. Equities
  3. FLGT Stock
  4. News Fulgent Genetics, Inc.
  5. Fulgent Genetics Reports Higher Q3 Non-GAAP EPS as Revenue More Than Doubles, Lifts 2021 Revenue Guidance